Loading...
TGAT
CNWKk
Market cap7mUSD
Oct 21, Last price  
1.80EUR
Name

CoDon AG

Chart & Performance

D1W1MN
TGAT:CNWKk chart
P/E
P/S
4.92
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
7.36%
Revenues
10m
+57.28%
00119,676,0001,522,0001,753,0002,145,0002,316,0002,693,0003,622,0004,510,0005,086,0005,622,0006,326,0005,696,0006,856,0006,233,0009,803,000
Net income
-9m
L-32.79%
00-1,444,000-923,000-1,678,000-1,433,000-1,010,000-2,381,000-2,684,000-2,493,000-2,866,000-3,650,000-6,578,000-6,271,000-12,629,000-13,869,000-9,322,000
CFO
-8m
L-15.90%
00000-2,334,065-1,564,342-2,108,000-2,974,000-3,617,000-5,878,485-8,138,000-9,529,000-9,457,000-7,953,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in 1993 and headquartered in Teltow, Germany, co.don AG operates as a global biopharmaceutical firm dedicated to the research, development, and marketing of cell-based pharmaceutical solutions. The company's core focus is on joint preservation and the regenerative repair of articular cartilage defects. Its offerings include Spherox, an advanced three-dimensional chondrocyte product specifically designed to address cartilage damage in adult knee joints. Additionally, co.don AG provides co.don chondrosphere, a therapy utilized for treating cartilage imperfections in younger patients across multiple joints, such as the hip, ankle, shoulder, elbow, and knees. These specialized treatments are primarily employed by orthopedic and trauma surgeons.
IPO date
Feb 01, 2001
Employees
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFY
2021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT